Daxor Corporation Announces Further Acquisitions And Increased Utilization Of Its BVA-100 Blood Volume Diagnostic Throughout The U.S.
Portfolio Pulse from Happy Mohamed
Daxor Corporation (DXR) has announced further acquisitions and increased utilization of its BVA-100 blood volume diagnostic in the U.S. The company has expanded its blood volume analysis into five of six hospitals in the Southeast and increased utilization for clinical use at two sites. The recent launch of Daxor's ezBVA Lab service is expected to contribute significantly to the growth of BVA sales. A six-facility hospital system in Northern Kentucky and Southeastern Indiana has begun utilizing Daxor's ezBVA Lab service. Two additional hospitals have expanded the use of BVA testing.

July 11, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Daxor's expansion into more hospitals and the launch of its ezBVA Lab service is expected to significantly boost BVA sales, potentially leading to increased revenues and a positive impact on the company's stock.
The news of Daxor's expansion into more hospitals and the launch of its new service, which is expected to significantly boost BVA sales, is directly related to the company's potential revenue growth. This could lead to increased investor interest and a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100